Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AndroBioSys Inc.

Latest From AndroBioSys Inc.

Treating Late-Stage Prostate Cancer

Prostate cancer was the cause of 28,666 deaths in 2008, or 10% of cancer deaths in the US, and roughly 186,000 men are diagnosed with the disease each year. Docetaxel, a chemotherapeutic agent, is the only FDA-approved drug to treat late-stage prostate cancer, leaving a significant need that many biotechs and pharmaceutical firms are trying to meet. Results are starting to roll in from several key clinical trials of late-stage prostate cancer therapies. Start-ups embarking on drug development may face significant competition.

AndroBioSys Inc.

AndroBioSys is pursuing a dual strategy for treating prostate disease: it's running a contract research business while it builds a therapeutic pipeline. One of the company's programs is based on the discovery of a novel enzyme that converts testosterone to dihydrotestosterone, which is the most potent activator of the androgen receptor. Another program focuses on a target on prostate cancer stem cells that makes them resistant to chemotherapy. The company is working on developing an assay to detect circulating prostate cancer stem cells, which could guide physicians in determining how aggressively to treat the patient. The next step would be to develop a therapy capable of eliminating such cells.

Start-Up Previews (03/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Treating Late-Stage Prostate Cancer," features profiles of AndroBioSys, Bellicum Pharmaceuticals, Colby Pharmaceuticals and Med Discovery. Plus these Start-Ups Across Health Care: AeonClad Biomedical, Arete Therapeutics, Bonovo Orthopedics and Thrasos Therapeutics.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AndroBioSys Inc.
  • Senior Management
  • Michael Zwick, PhD, CEO
  • Contact Info
  • AndroBioSys Inc.
    Phone: (716) 849-6818
    73 High St.
    Buffalo, NY 14203-1149